67 related articles for article (PubMed ID: 36996321)
1. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.
Chen H; Duan X; Deng X; Huang Y; Zhou X; Zhang S; Zhang X; Liu P; Yang C; Liu G; Ren Q; Xiong Y; Zhu B; Zhang J; Xiang T
Cancer Immunol Res; 2023 Jun; 11(6):830-846. PubMed ID: 36996321
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma.
Chen C; Wang C; Pang R; Liu H; Yin W; Chen J; Tao L
J Transl Med; 2023 Apr; 21(1):278. PubMed ID: 37098551
[TBL] [Abstract][Full Text] [Related]
3. Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma.
Yuan Q; Chen BH; Huang DJ; Zhang R
Braz J Med Biol Res; 2023; 56():e12638. PubMed ID: 37493769
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus BRLF1 Induces PD-L1 Expression in Nasopharyngeal Carcinoma Cells.
Wu CC; Chen MS; Lee TY; Huang TS; Cho DY; Chen JY
Viral Immunol; 2024 Mar; 37(2):115-123. PubMed ID: 38498796
[TBL] [Abstract][Full Text] [Related]
5. STIM1-regulated exosomal EBV-LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma.
Deng Y; Liu X; Huang Y; Ye J; He Q; Luo Y; Chen Y; Li Q; Lin Y; Liang R; Li Y; Wei J; Zhang J
Cell Oncol (Dordr); 2023 Aug; 46(4):987-1000. PubMed ID: 36917356
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of KLF5 by EBER1 via the ERK signaling pathway in EBV-positive nasopharyngeal carcinoma cells: implications for latent EBV infection.
Hu J; Xin F; Liu W; Gong Z; Zhang Y; Liu S
J Gen Virol; 2024 May; 105(5):. PubMed ID: 38747699
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta increases NK cell cytotoxicity against tumor cells in patients with nasopharyngeal carcinoma via tumor necrosis factor apoptosis-inducing ligand.
Makowska A; Franzen S; Braunschweig T; Denecke B; Shen L; Baloche V; Busson P; Kontny U
Cancer Immunol Immunother; 2019 Aug; 68(8):1317-1329. PubMed ID: 31312900
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region.
Dias JM; Santana IVV; da Silva VD; Carvalho AL; Arantes LMRB
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233023
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
10. Post cross-linked ROS-responsive poly(β-amino ester)-plasmid polyplex NPs for gene therapy of EBV-associated nasopharyngeal carcinoma.
Yuan C; Chang S; Zhang C; Dong D; Ding J; Mahdavian AR; Hu Z; Sun L; Tan S
J Mater Chem B; 2024 Mar; 12(12):3129-3143. PubMed ID: 38451208
[TBL] [Abstract][Full Text] [Related]
11. The immune escape mechanism of nasopharyngeal carcinoma.
Li X; Guo Y; Xiao M; Zhang W
FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
[TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities.
Liu Q; Bode AM; Chen X; Luo X
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189023. PubMed ID: 37979733
[TBL] [Abstract][Full Text] [Related]
13. Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes.
Singh DR; Nelson SE; Pawelski AS; Cantres-Velez JA; Kansra AS; Pauly NP; Bristol JA; Hayes M; Ohashi M; Casco A; Lee D; Fogarty SA; Lambert PF; Johannsen EC; Kenney SC
PLoS Pathog; 2022 Oct; 18(10):e1010868. PubMed ID: 36190982
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
[TBL] [Abstract][Full Text] [Related]
15. E3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies.
Zhou Z; Zheng K; Zhou S; Yang Y; Chen J; Jin X
J Mol Med (Berl); 2023 Dec; 101(12):1543-1565. PubMed ID: 37796337
[TBL] [Abstract][Full Text] [Related]
16. The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma.
Li S; Dai W; Kam NW; Zhang J; Lee VHF; Ren X; Kwong DL
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610990
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
Yeo BSY; Lee RS; Lim NE; Tan E; Jang IJH; Toh HC; Lim CM
Oral Oncol; 2024 May; 152():106786. PubMed ID: 38615584
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Assessing the Clinical Implications of Epstein-Barr Virus Infection and Their Application to the Diagnosis and Treatment of Nasopharyngeal Carcinoma.
Yoshizaki T; Kondo S; Dochi H; Kobayashi E; Mizokami H; Komura S; Endo K
Microorganisms; 2023 Dec; 12(1):. PubMed ID: 38276183
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.
Prasad M; Ponnalagu S; Zeng Q; Luu K; Lang SM; Wong HY; Cheng MS; Wu M; Mallilankaraman K; Sobota RM; Lim YT; Wang LC; Goh CK; Tay KXJ; Loh KS; Wang CI; Lee WH; Goh BC; Lim CM; Schwarz H
Cancer Immunol Immunother; 2022 Nov; 71(11):2583-2596. PubMed ID: 35299256
[TBL] [Abstract][Full Text] [Related]
20. Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas.
Jaeger HK; Davis DA; Nair A; Shrestha P; Stream A; Yaparla A; Yarchoan R
Sci Rep; 2023 Jul; 13(1):11596. PubMed ID: 37463943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
